Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Interferon-inducible TRIM22 contributes to maintenance of HIV-1 proviral latency in T cell lines.

Turrini F, Saliu F, Forlani G, Das AT, Van Lint C, Accolla RS, Berkhout B, Poli G, Vicenzi E.

Virus Res. 2019 May 25;269:197631. doi: 10.1016/j.virusres.2019.05.009. [Epub ahead of print]

PMID:
31136823
2.

Heterogeneous HIV-1 Reactivation Patterns of Disulfiram and Combined Disulfiram+Romidepsin Treatments.

Kula A, Delacourt N, Bouchat S, Darcis G, Avettand-Fenoel V, Verdikt R, Corazza F, Necsoi C, Vanhulle C, Bendoumou M, Burny A, De Wit S, Rouzioux C, Rohr O, Van Lint C.

J Acquir Immune Defic Syndr. 2019 Apr 15;80(5):605-613. doi: 10.1097/QAI.0000000000001958.

PMID:
30768485
3.

Stop HUSHing on SIV/HIV.

Van Lint C.

Nat Microbiol. 2018 Dec;3(12):1336-1338. doi: 10.1038/s41564-018-0308-2. No abstract available.

PMID:
30478387
4.

Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3.

Sarracino A, Gharu L, Kula A, Pasternak AO, Avettand-Fenoel V, Rouzioux C, Bardina M, De Wit S, Benkirane M, Berkhout B, Van Lint C, Marcello A.

MBio. 2018 Nov 13;9(6). pii: e02158-18. doi: 10.1128/mBio.02158-18.

5.

The Molecular Biology of HIV Latency.

Khoury G, Darcis G, Lee MY, Bouchat S, Van Driessche B, Purcell DFJ, Van Lint C.

Adv Exp Med Biol. 2018;1075:187-212. doi: 10.1007/978-981-13-0484-2_8. Review.

PMID:
30030794
6.

Immunity drives TET1 regulation in cancer through NF-κB.

Collignon E, Canale A, Al Wardi C, Bizet M, Calonne E, Dedeurwaerder S, Garaud S, Naveaux C, Barham W, Wilson A, Bouchat S, Hubert P, Van Lint C, Yull F, Sotiriou C, Willard-Gallo K, Noel A, Fuks F.

Sci Adv. 2018 Jun 20;4(6):eaap7309. doi: 10.1126/sciadv.aap7309. eCollection 2018 Jun.

7.

Molecular Control of HIV and SIV Latency.

Darcis G, Van Driessche B, Bouchat S, Kirchhoff F, Van Lint C.

Curr Top Microbiol Immunol. 2018;417:1-22. doi: 10.1007/82_2017_74.

PMID:
29071474
8.

Self-Monitoring Kidney Function Post Transplantation: Reliability of Patient-Reported Data.

van Lint C, Wang W, van Dijk S, Brinkman WP, Rövekamp TJ, Neerincx MA, Rabelink TJ, van der Boog PJ.

J Med Internet Res. 2017 Sep 26;19(9):e316. doi: 10.2196/jmir.7542.

9.

Primate lentiviruses use at least three alternative strategies to suppress NF-κB-mediated immune activation.

Hotter D, Krabbe T, Reith E, Gawanbacht A, Rahm N, Ayouba A, Van Driessche B, Van Lint C, Peeters M, Kirchhoff F, Sauter D.

PLoS Pathog. 2017 Aug 31;13(8):e1006598. doi: 10.1371/journal.ppat.1006598. eCollection 2017 Aug.

10.

On the way to find a cure: Purging latent HIV-1 reservoirs.

Schwartz C, Bouchat S, Marban C, Gautier V, Van Lint C, Rohr O, Le Douce V.

Biochem Pharmacol. 2017 Dec 15;146:10-22. doi: 10.1016/j.bcp.2017.07.001. Epub 2017 Jul 4. Review.

PMID:
28687465
11.

Pregnancy and pelvic girdle pain: Analysis of pelvic belt on pain.

Bertuit J, Van Lint CE, Rooze M, Feipel V.

J Clin Nurs. 2018 Jan;27(1-2):e129-e137. doi: 10.1111/jocn.13888. Epub 2017 Nov 3.

PMID:
28544276
12.

Renal transplant patient acceptance of a self-management support system.

Wang W, van Lint CL, Brinkman WP, Rövekamp TJM, van Dijk S, van der Boog PJM, Neerincx MA.

BMC Med Inform Decis Mak. 2017 May 8;17(1):58. doi: 10.1186/s12911-017-0456-y.

13.

Repression of Human T-lymphotropic virus type 1 Long Terminal Repeat sense transcription by Sp1 recruitment to novel Sp1 binding sites.

Fauquenoy S, Robette G, Kula A, Vanhulle C, Bouchat S, Delacourt N, Rodari A, Marban C, Schwartz C, Burny A, Rohr O, Van Driessche B, Van Lint C.

Sci Rep. 2017 Mar 3;7:43221. doi: 10.1038/srep43221.

14.

Corrigendum: HIC1 controls cellular- and HIV-1- gene transcription via interactions with CTIP2 and HMGA1.

Le Douce V, Forouzanfar F, Eilebrecht S, Van Driessche B, Ait-Ammar A, Verdikt R, Kurashige Y, Marban C, Gautier V, Candolfi E, Benecke AG, Van Lint C, Rohr O, Schwartz C.

Sci Rep. 2017 Feb 10;7:39569. doi: 10.1038/srep39569. No abstract available.

15.

HIV Latency: Should We Shock or Lock?

Darcis G, Van Driessche B, Van Lint C.

Trends Immunol. 2017 Mar;38(3):217-228. doi: 10.1016/j.it.2016.12.003. Epub 2017 Jan 7. Review.

PMID:
28073694
16.

Limited HIV-1 Reactivation in Resting CD4+ T cells from Aviremic Patients under Protease Inhibitors.

Kumar A, Abbas W, Bouchat S, Gatot JS, Pasquereau S, Kabeya K, Clumeck N, De Wit S, Van Lint C, Herbein G.

Sci Rep. 2016 Dec 6;6:38313. doi: 10.1038/srep38313.

17.

Reactivation of simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques.

Gama L, Abreu CM, Shirk EN, Price SL, Li M, Laird GM, Pate KA, Wietgrefe SW, O'Connor SL, Pianowski L, Haase AT, Van Lint C, Siliciano RF, Clements JE; LRA-SIV Study Group.

AIDS. 2017 Jan 2;31(1):5-14.

18.

Exploring the anatomical HIV reservoirs: role of the testicular tissue.

Darcis G, Coombs RW, Van Lint C.

AIDS. 2016 Nov 28;30(18):2891-2893. No abstract available.

19.

Reactivation capacity by latency-reversing agents ex vivo correlates with the size of the HIV-1 reservoir.

Darcis G, Bouchat S, Kula A, Van Driessche B, Delacourt N, Vanhulle C, Avettand-Fenoel V, De Wit S, Rohr O, Rouzioux C, Van Lint C.

AIDS. 2017 Jan 14;31(2):181-189. doi: 10.1097/QAD.0000000000001290.

PMID:
27755105
20.

HIC1 controls cellular- and HIV-1- gene transcription via interactions with CTIP2 and HMGA1.

Le Douce V, Forouzanfar F, Eilebrecht S, Van Driessche B, Ait-Ammar A, Verdikt R, Kurashige Y, Marban C, Gautier V, Candolfi E, Benecke AG, Van Lint C, Rohr O, Schwartz C.

Sci Rep. 2016 Oct 11;6:34920. doi: 10.1038/srep34920. Erratum in: Sci Rep. 2017 Feb 10;7:39569.

21.

Characterization of new RNA polymerase III and RNA polymerase II transcriptional promoters in the Bovine Leukemia Virus genome.

Van Driessche B, Rodari A, Delacourt N, Fauquenoy S, Vanhulle C, Burny A, Rohr O, Van Lint C.

Sci Rep. 2016 Aug 22;6:31125. doi: 10.1038/srep31125.

22.

Preclinical shock strategies to reactivate latent HIV-1: an update.

Darcis G, Van Driessche B, Van Lint C.

Curr Opin HIV AIDS. 2016 Jul;11(4):388-93. doi: 10.1097/COH.0000000000000288. Review.

PMID:
27259046
23.

Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation.

Noel N, Peña R, David A, Avettand-Fenoel V, Erkizia I, Jimenez E, Lecuroux C, Rouzioux C, Boufassa F, Pancino G, Venet A, Van Lint C, Martinez-Picado J, Lambotte O, Sáez-Cirión A, Prado JG.

J Virol. 2016 Jun 10;90(13):6148-6158. doi: 10.1128/JVI.00419-16. Print 2016 Jul 1.

24.

Tuning of AKT-pathway by Nef and its blockade by protease inhibitors results in limited recovery in latently HIV infected T-cell line.

Kumar A, Abbas W, Colin L, Khan KA, Bouchat S, Varin A, Larbi A, Gatot JS, Kabeya K, Vanhulle C, Delacourt N, Pasquereau S, Coquard L, Borch A, König R, Clumeck N, De Wit S, Rohr O, Rouzioux C, Fulop T, Van Lint C, Herbein G.

Sci Rep. 2016 Apr 14;6:24090. doi: 10.1038/srep24090.

25.

HIV-1 transcriptional silencing caused by TRIM22 inhibition of Sp1 binding to the viral promoter.

Turrini F, Marelli S, Kajaste-Rudnitski A, Lusic M, Van Lint C, Das AT, Harwig A, Berkhout B, Vicenzi E.

Retrovirology. 2015 Dec 18;12:104. doi: 10.1186/s12977-015-0230-0.

26.

Sequential treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1.

Bouchat S, Delacourt N, Kula A, Darcis G, Van Driessche B, Corazza F, Gatot JS, Melard A, Vanhulle C, Kabeya K, Pardons M, Avettand-Fenoel V, Clumeck N, De Wit S, Rohr O, Rouzioux C, Van Lint C.

EMBO Mol Med. 2016 Feb 1;8(2):117-38. doi: 10.15252/emmm.201505557.

27.

Patient experiences with self-monitoring renal function after renal transplantation: results from a single-center prospective pilot study.

van Lint CL, van der Boog PJ, Wang W, Brinkman WP, Rövekamp TJ, Neerincx MA, Rabelink TJ, van Dijk S.

Patient Prefer Adherence. 2015 Dec 7;9:1721-31. doi: 10.2147/PPA.S92108. eCollection 2015.

28.

Prdm12 specifies V1 interneurons through cross-repressive interactions with Dbx1 and Nkx6 genes in Xenopus.

Thélie A, Desiderio S, Hanotel J, Quigley I, Van Driessche B, Rodari A, Borromeo MD, Kricha S, Lahaye F, Croce J, Cerda-Moya G, Ordoño Fernandez J, Bolle B, Lewis KE, Sander M, Pierani A, Schubert M, Johnson JE, Kintner CR, Pieler T, Van Lint C, Henningfeld KA, Bellefroid EJ, Van Campenhout C.

Development. 2015 Oct 1;142(19):3416-28. doi: 10.1242/dev.121871.

29.

Epigenetic control of HIV-1 post integration latency: implications for therapy.

Kumar A, Darcis G, Van Lint C, Herbein G.

Clin Epigenetics. 2015 Sep 24;7:103. doi: 10.1186/s13148-015-0137-6. eCollection 2015. Review.

30.

An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.

Darcis G, Kula A, Bouchat S, Fujinaga K, Corazza F, Ait-Ammar A, Delacourt N, Melard A, Kabeya K, Vanhulle C, Van Driessche B, Gatot JS, Cherrier T, Pianowski LF, Gama L, Schwartz C, Vila J, Burny A, Clumeck N, Moutschen M, De Wit S, Peterlin BM, Rouzioux C, Rohr O, Van Lint C.

PLoS Pathog. 2015 Jul 30;11(7):e1005063. doi: 10.1371/journal.ppat.1005063. eCollection 2015 Jul.

31.

Application of a point of care creatinine device for trend monitoring in kidney transplant patients: fit for purpose?

van Lint CL, van der Boog PJ, Romijn FP, Schenk PW, van Dijk S, Rövekamp TJ, Kessler A, Siekmann L, Rabelink TJ, Cobbaert CM.

Clin Chem Lab Med. 2015 Sep 1;53(10):1547-56. doi: 10.1515/cclm-2014-0932.

PMID:
25719331
32.

Differential regulation of NF-κB-mediated proviral and antiviral host gene expression by primate lentiviral Nef and Vpu proteins.

Sauter D, Hotter D, Van Driessche B, Stürzel CM, Kluge SF, Wildum S, Yu H, Baumann B, Wirth T, Plantier JC, Leoz M, Hahn BH, Van Lint C, Kirchhoff F.

Cell Rep. 2015 Feb 3;10(4):586-99. doi: 10.1016/j.celrep.2014.12.047. Epub 2015 Jan 22.

33.

HMGA1 recruits CTIP2-repressed P-TEFb to the HIV-1 and cellular target promoters.

Eilebrecht S, Le Douce V, Riclet R, Targat B, Hallay H, Van Driessche B, Schwartz C, Robette G, Van Lint C, Rohr O, Benecke AG.

Nucleic Acids Res. 2014 Apr;42(8):4962-71. doi: 10.1093/nar/gku168. Epub 2014 Mar 11.

34.

The Prdm13 histone methyltransferase encoding gene is a Ptf1a-Rbpj downstream target that suppresses glutamatergic and promotes GABAergic neuronal fate in the dorsal neural tube.

Hanotel J, Bessodes N, Thélie A, Hedderich M, Parain K, Van Driessche B, Brandão Kde O, Kricha S, Jorgensen MC, Grapin-Botton A, Serup P, Van Lint C, Perron M, Pieler T, Henningfeld KA, Bellefroid EJ.

Dev Biol. 2014 Feb 15;386(2):340-57. doi: 10.1016/j.ydbio.2013.12.024. Epub 2013 Dec 24.

35.

HIV-1 chromatin, transcription, and the regulatory protein Tat.

Colin L, Verdin E, Van Lint C.

Methods Mol Biol. 2014;1087:85-101. doi: 10.1007/978-1-62703-670-2_8.

PMID:
24158816
36.

CTIP2 is a negative regulator of P-TEFb.

Cherrier T, Le Douce V, Eilebrecht S, Riclet R, Marban C, Dequiedt F, Goumon Y, Paillart JC, Mericskay M, Parlakian A, Bausero P, Abbas W, Herbein G, Kurdistani SK, Grana X, Van Driessche B, Schwartz C, Candolfi E, Benecke AG, Van Lint C, Rohr O.

Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):12655-60. doi: 10.1073/pnas.1220136110. Epub 2013 Jul 12.

37.

HIV-1 transcription and latency: an update.

Van Lint C, Bouchat S, Marcello A.

Retrovirology. 2013 Jun 26;10:67. doi: 10.1186/1742-4690-10-67. Review.

38.

Towards an HIV cure: a global scientific strategy.

International AIDS Society Scientific Working Group on HIV Cure, Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N, Chun TW, Churchill M, Di Mascio M, Katlama C, Lafeuillade A, Landay A, Lederman M, Lewin SR, Maldarelli F, Margolis D, Markowitz M, Martinez-Picado J, Mullins JI, Mellors J, Moreno S, O'Doherty U, Palmer S, Penicaud MC, Peterlin M, Poli G, Routy JP, Rouzioux C, Silvestri G, Stevenson M, Telenti A, Van Lint C, Verdin E, Woolfrey A, Zaia J, Barré-Sinoussi F.

Nat Rev Immunol. 2012 Jul 20;12(8):607-14. doi: 10.1038/nri3262. Review.

39.

Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients.

Bouchat S, Gatot JS, Kabeya K, Cardona C, Colin L, Herbein G, De Wit S, Clumeck N, Lambotte O, Rouzioux C, Rohr O, Van Lint C.

AIDS. 2012 Jul 31;26(12):1473-82. doi: 10.1097/QAD.0b013e32835535f5. Erratum in: AIDS. 2013 Jun 19;27(10):1683.

PMID:
22555163
40.

Host-pathogen interactome mapping for HTLV-1 and -2 retroviruses.

Simonis N, Rual JF, Lemmens I, Boxus M, Hirozane-Kishikawa T, Gatot JS, Dricot A, Hao T, Vertommen D, Legros S, Daakour S, Klitgord N, Martin M, Willaert JF, Dequiedt F, Navratil V, Cusick ME, Burny A, Van Lint C, Hill DE, Tavernier J, Kettmann R, Vidal M, Twizere JC.

Retrovirology. 2012 Mar 29;9:26. doi: 10.1186/1742-4690-9-26.

41.

LSD1 cooperates with CTIP2 to promote HIV-1 transcriptional silencing.

Le Douce V, Colin L, Redel L, Cherrier T, Herbein G, Aunis D, Rohr O, Van Lint C, Schwartz C.

Nucleic Acids Res. 2012 Mar;40(5):1904-15. doi: 10.1093/nar/gkr857. Epub 2011 Nov 8. Erratum in: Nucleic Acids Res. . 2014 Apr;42(6):4141.

42.

Chromatin disruption in the promoter of bovine leukemia virus during transcriptional activation.

Colin L, Dekoninck A, Reichert M, Calao M, Merimi M, Van den Broeke A, Vierendeel V, Cleuter Y, Burny A, Rohr O, Van Lint C.

Nucleic Acids Res. 2011 Dec;39(22):9559-73. doi: 10.1093/nar/gkr671. Epub 2011 Sep 2.

43.

Purification of SUMO-1 modified IκBα and complex formation with NF-κB.

Lens Z, Dewitte F, Van Lint C, de Launoit Y, Villeret V, Verger A.

Protein Expr Purif. 2011 Dec;80(2):211-6. doi: 10.1016/j.pep.2011.06.009. Epub 2011 Jun 25.

PMID:
21708266
44.

The HTLV-1 Tax protein inhibits formation of stress granules by interacting with histone deacetylase 6.

Legros S, Boxus M, Gatot JS, Van Lint C, Kruys V, Kettmann R, Twizere JC, Dequiedt F.

Oncogene. 2011 Sep 22;30(38):4050-62. doi: 10.1038/onc.2011.120. Epub 2011 May 2.

45.

The AP-1 binding sites located in the pol gene intragenic regulatory region of HIV-1 are important for viral replication.

Colin L, Vandenhoudt N, de Walque S, Van Driessche B, Bergamaschi A, Martinelli V, Cherrier T, Vanhulle C, Guiguen A, David A, Burny A, Herbein G, Pancino G, Rohr O, Van Lint C.

PLoS One. 2011 Apr 19;6(4):e19084. doi: 10.1371/journal.pone.0019084.

46.

Synthesis, biological evaluation and molecular modeling studies of quinolonyl diketo acid derivatives: new structural insight into the HIV-1 integrase inhibition.

Vandurm P, Guiguen A, Cauvin C, Georges B, Le Van K, Michaux C, Cardona C, Mbemba G, Mouscadet JF, Hevesi L, Van Lint C, Wouters J.

Eur J Med Chem. 2011 May;46(5):1749-56. doi: 10.1016/j.ejmech.2011.02.028. Epub 2011 Feb 22.

PMID:
21385662
47.

Solution structure of the N-terminal transactivation domain of ERM modified by SUMO-1.

Lens Z, Dewitte F, Monté D, Baert JL, Bompard C, Sénéchal M, Van Lint C, de Launoit Y, Villeret V, Verger A.

Biochem Biophys Res Commun. 2010 Aug 13;399(1):104-10. doi: 10.1016/j.bbrc.2010.07.049. Epub 2010 Jul 18.

PMID:
20647002
48.

HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals.

Trono D, Van Lint C, Rouzioux C, Verdin E, Barré-Sinoussi F, Chun TW, Chomont N.

Science. 2010 Jul 9;329(5988):174-80. doi: 10.1126/science.1191047. Review.

PMID:
20616270
49.

DNA cytosine methylation in the bovine leukemia virus promoter is associated with latency in a lymphoma-derived B-cell line: potential involvement of direct inhibition of cAMP-responsive element (CRE)-binding protein/CRE modulator/activation transcription factor binding.

Pierard V, Guiguen A, Colin L, Wijmeersch G, Vanhulle C, Van Driessche B, Dekoninck A, Blazkova J, Cardona C, Merimi M, Vierendeel V, Calomme C, Nguyên TL, Nuttinck M, Twizere JC, Kettmann R, Portetelle D, Burny A, Hirsch I, Rohr O, Van Lint C.

J Biol Chem. 2010 Jun 18;285(25):19434-49. doi: 10.1074/jbc.M110.107607. Epub 2010 Apr 22.

50.

Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies.

Colin L, Van Lint C.

Retrovirology. 2009 Dec 4;6:111. doi: 10.1186/1742-4690-6-111. Review.

Supplemental Content

Loading ...
Support Center